FLT3 and acute myeloid leukemia: A phase III LACEWING trial subsequently evaluated gilteritinib + azacitidine vs. azacitidine alone in newly diagnosed FLT3-mutated older AML, which found gilteritinib + azacitidine with a significantly higher CR rate (58.1% vs. 26.5%) but similar OS (9.8 months vs. 8.9 months) between the two groups.